Metabolic Signatures and Biomarkers in Schizophrenia
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated
schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug
aripiprazole and compare that to lipid perturbations induced by risperidone. These drugs have
inherently different risk for metabolic adverse effects and patients respond to them
differently. Metabolic signatures for the drugs capture significant biochemical information
that could explain part of the basis for varied drug response within individuals and will
highlight pathways implicated in drug action and in disease pathogenesis possibly enabling
new drug design strategies. In addition, we will compare patients to healthy controls at
baseline in regard lipid profiles.